Medical Disclaimer

Updated: September 8, 2026 — referral description corrected.

What Peptide Dossier is

Peptide Dossier is a reference site covering peptides, GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide, and others), and related compounds. We compile information from peer-reviewed research, FDA filings, clinical practice guidelines, manufacturer labeling, and reputable secondary sources. Every guide on this site is written to help a curious adult understand the landscape.

What it is not

Peptide Dossier is not a doctor, pharmacist, nurse, or other healthcare professional. It cannot take a history, examine you, review your labs, or weigh your medication list. It cannot prescribe. Nothing on this Site should be interpreted as:

• A diagnosis of any medical condition
• A recommendation to start, stop, or change a medication
• An endorsement of any compound for any specific person
• A substitute for evaluation by a licensed clinician
• Legal advice about the regulatory status of any peptide

Why this matters for peptides specifically

Peptides occupy a complicated space. Some are FDA-approved prescription drugs (semaglutide, tirzepatide, oxytocin, octreotide). Some are compounded under 503A or 503B authority with varying rules. Some are sold as "research chemicals" with no quality guarantees. Many popular peptides (BPC-157, TB-500, ipamorelin, MK-677) lack FDA approval for any human indication, and the FDA has moved to restrict several of them.

Dosing ranges, half-lives, side effect profiles, and injection technique described on this site reflect what is reported in research literature and clinical practice. Those figures are context, not instructions. Individual response varies based on age, weight, sex, comorbidities, concurrent medications, kidney and liver function, and many other factors a clinician must assess.

Drug interactions and comorbidities

GLP-1 receptor agonists interact with gastroparesis medications, anti-diabetic medications, oral contraceptives, and procedures involving anesthesia. Peptides affecting growth hormone pathways interact with diabetes management and cancer risk. Self-directed use without clinician oversight can cause hypoglycemia, pancreatitis, thyroid effects, and other serious outcomes. If you have an existing condition, take prescription medications, are pregnant or nursing, or are planning surgery, do not act on anything on this Site without clinician review.

Emergencies

If you are experiencing a medical emergency, call 911 (in the United States) or your local emergency number immediately. Do not use this Site for emergency guidance.

Sources and errors

We cite primary sources where possible. Medical knowledge evolves; FDA guidance changes; clinical trials report new results. If you rely on a specific claim from this site for a real decision, verify it against the underlying source or a current clinician. If you find an error, let us know and we will correct it.

Provider referrals

We receive no compensation for referrals or links. Rankings reflect editorial judgment. A favorable provider mention does not establish that a treatment is appropriate for your situation; prescription eligibility requires a clinician's assessment.

See also: Privacy Policy and Terms of Use.